Press coverage about Cellectis (NASDAQ:CLLS) has been trending positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cellectis earned a news impact score of 0.25 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.075306807567 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several research analysts recently weighed in on CLLS shares. Zacks Investment Research lowered shares of Cellectis from a “buy” rating to a “hold” rating in a research note on Thursday, November 16th. ValuEngine lowered shares of Cellectis from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Oppenheimer reissued an “outperform” rating and set a $40.00 price objective on shares of Cellectis in a research note on Thursday, December 28th. Finally, BidaskClub raised shares of Cellectis from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Cellectis currently has a consensus rating of “Buy” and an average price target of $37.67.
Cellectis (NASDAQ CLLS) opened at $32.71 on Wednesday. Cellectis has a one year low of $21.19 and a one year high of $35.07. The firm has a market cap of $1,151.86, a P/E ratio of -13.57 and a beta of 1.94.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.